HER2 and p53 Expression in Marjolin’s Ulcer

2021 ◽  
Author(s):  
xia chen ◽  
Chu Zhi Gang ◽  
Jin Dong May ◽  
Xiao Yan ◽  
Ma Wen
Keyword(s):  
Clinicopathological Characteristics ◽  
P53 Expression ◽  
Course Of Disease ◽  
Diagnosis And Prognosis ◽  
Pathological Type ◽  
Positive Expression ◽  
Marjolin’S Ulcer ◽  
Skin Ulcers ◽  
Positive Rate ◽  
Expression Rate

Abstract Background：Marjolin's ulcer is a malignant tumor that is different from other skin ulcers, and its pathogenesis is not yet clear. The diagnosis and prognosis of Marjolin's ulcer lack valuable marks on immunohistochemistry (IHC).Methods: In this study, we detected the expression of HER2 and p53 in Majorlin’s ulcer with immunohistochemistry, and retrospectively analyze the clinicopathological characteristics of Marjolin's ulcer samples.Results: Our results showed that no HER2 but p53 was detected in Majorlin’s Ulcer samples. Meanwhile, by statistic analysis we found that the positive expression rate of p53 in Majorlin’s Ulcer samples was associated with sex, course of disease, ulcer size, pathological type of ulcer canceration, and degree of tumor differentiation. Furthermore, we showed that the positive rate of p53 was proportional to the malignancy degree of Marjolin’s ulcer. Conclusions:Our results of this study will lay a foundation for diagnosis of Marjolin's ulcer and even prevention of Marjolin's ulcer progression

scholarly journals Expression features of androgen receptor in special subtypes of breast cancer

2019 ◽  
Author(s):  
Guomin Xiang ◽  
Jing Liu ◽  
Lu Cao ◽  
Cong Xu ◽  
Fang Liu ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Androgen Receptor ◽  
Clinical Work ◽  
Routine Testing ◽  
Positive Expression ◽  
Apocrine Differentiation ◽  
Positive Rate ◽  
Expression Rate ◽  
Medical University

Abstract Purpose The important role of the androgen receptor (AR) in invasive carcinoma of no specific type (NST) has been increasingly recognised. However, only a few studies have been reported in special subtypes of breast cancer. Thus, we aim to investigate the AR expression and its expression features in special subtypes of breast cancer. Methods This study collected clinicopathological data of 718 special subtypes of breast cancer from Tianjin Medical University Cancer Institute and Hospital. Immunohistochemical staining of AR and other biomarkers was performed. Results If the threshold of AR is ≥ 1%, the positive rate of AR in specific subtypes of breast cancer is 77.9% (559/718) of cases. Compared with the threshold of AR is ≥ 10%, the positive percentage of AR in each subtype of breast cancer increases about 10%. The positive expression rate of AR in carcinomas with apocrine differentiation is highest, and the coloration intensity is much stronger than that of other subtypes. The positive expression rate of AR is lowest in metaplastic carcinomas, almost negative; the positive expression rate of AR in invasive lobular carcinomas (ILCs), invasive micropapillary carcinomas (IMPCs), invasive papillary carcinomas (IPCs), and is mucinous carcinomas about 70.0%–80.0%. Conclusions The expression features of AR in special subtypes of breast cancer vary in different subtypes, and to some extent, AR may be a useful biomarker for clinical diagnosis. Routine testing of AR has a certain guiding significance for clinical work. In addition, AR is expected to treat carcinomas with apocrine differentiation as a target.

Invasive penile carcinoma: Are p16, p53 and HPV ISH prognostically significant?

2015 ◽  
Vol 33 (7_suppl) ◽  
pp. 394-394
Author(s):  
Jasreman Dhillon ◽  
Anders E. Berglund ◽  
Julio Pow-Sang ◽  
Philippe E. Spiess ◽  
Anthony M. Magliocco
Keyword(s):  
Tumor Cells ◽  
Staining Intensity ◽  
Hpv Infection ◽  
Clinicopathological Characteristics ◽  
Hazard Ratio ◽  
Penile Carcinoma ◽  
P53 Expression ◽  
Kaplan Meier ◽  
Significant Difference ◽  
Low Incidence

394 Background: Penile carcinoma accounts for 0.4% to 0.6% of all malignancies in men. Due to its low incidence the prognostic role of clinicopathological characteristics, p16, p53 and HPV infection remains unclear. We report our experience with p16, p53 and HPV ISH (types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58 and 66) in determining the aggressive nature of this carcinoma. Methods: A tissue microarray (TMA) of 57 cases of invasive penile squamous cell carcinomas was immunohistochemically stained with immunohistochemical stains p16 and p53. HPV ISH was performed as well. The TMA slides were scored semi quantitatively by a specialized genitourinary surgical pathologist. The H score was calculated for p53 using a combination of staining intensity and extent according to the following formula: H score = 1 x % of tumor cells with weak staining + 2 x % of tumor cells with moderate staining + 3 x % of tumor cells with strong staining, resulting in a total score of 0 – 300. Calculations for p53 were done considering values above 0 as positive. For p16 and HPV ISH, the results were recorded as negative or positive. The overall survival curves for up to 60 months were estimated by Kaplan-Meier (KM) method. Results: HPV ISH was positive in 23 cases and p16 was positive in 23 cases as well. However, there were 9 discordant cases between the two (p16+/HPV ISH- = 5; p16-/HPV ISH+ = 4). p53 was positive in 39 cases. Tumors positive for HPV ISH had a better survival as compared to HPV ISH negative tumors (p = 0.0040; Hazard ratio 4.991). Whereas p16 (p = 0.206; Hazard ratio 1.838) and p53 (p = 0.1582; Hazard ratio 0.5198) were not significantly associated with survival at 60 months. Conclusions: Overall HPV positive penile carcinomas appear to have a distinct biology with better prognosis. There is no significant difference in survival for tumors with different p16 and p53 expression.

scholarly journals Correlations of Human Epithelial Growth Factor Receptor 2 Overexpression with MUC2, MUC5AC, MUC6, p53, and Clinicopathological Characteristics in Gastric Cancer Patients with Curative Resection

2015 ◽  
Vol 2015 ◽  
pp. 1-8 ◽  
Author(s):  
Kwang Kuk Park ◽  
Song I Yang ◽  
Kyung Won Seo ◽  
Ki Young Yoon ◽  
Sang Ho Lee ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Cancer Patients ◽  
Growth Factor Receptor ◽  
Clinicopathological Characteristics ◽  
Her2 Overexpression ◽  
Her2 Expression ◽  
Her2 Positive ◽  
Poor Prognostic Factor ◽  
P53 Expression ◽  
Gastric Cancer Patients

Background. The purpose of this study was to evaluate the relationships between HER2 overexpression in the tumor and MUC2, MUC5AC, MUC6, and p53 status and clinicopathological characteristics of gastric cancer patients.Methods. This retrospective study included 282 consecutive patients with gastric cancer who underwent surgery at the Kosin University Gospel Hospital between April 2011 and December 2012. All tumor samples were examined for HER2 expression by immunohistochemistry (IHC) and MUC2, MUC5AC, MUC6, and p53 expression by staining. A retrospective review of the medical records was conducted to determine the correlation between the presence of HER2 overexpression and clinicopathological factors.Results. The HER2-positive rate was 18.1%. Although no association was found between HER2 expression and MUC5AC, the expression of MUC2, MUC6, and p53 was significantly correlated with HER2 positivity, respectively (P= 0.004, 0.037, 0.002). Multivariate analysis revealed that HER2 overexpression and nodal status were independent prognostic factors.Conclusions. HER2 overexpression in gastric carcinoma is an independent poor prognostic factor.

scholarly journals HKDC1 promotes the tumorigenesis and glycolysis in lung adenocarcinoma via regulating AMPK/mTOR signaling pathway2

2020 ◽  
Author(s):  
Xinyu Wang ◽  
Bowen Shi ◽  
Yue Zhao ◽  
Qijue Lu ◽  
Xiang Fei ◽  
...  
Keyword(s):  
Lung Adenocarcinoma ◽  
Clinicopathological Characteristics ◽  
Mtor Signaling ◽  
Mtor Signaling Pathway ◽  
Positive Expression ◽  
Promising Therapeutic Target ◽  
Bioinformatics Study ◽  
Polymerase Chain

Abstract Background: Hexokinase domain component 1 (HKDC1) plays an oncogenic role in certain types of cancer, such as lymphoma, liver cancer, and breast cancer. Previous bioinformatics study revealed that HKDC1 was significantly upregulated in lung adenocarcinoma (LUAD). However, its biological functions and potential mechanism in LUAD have not been studied.Methods: We performed bioinformatics analysis, quantitative real-time polymerase chain reaction (qRT-PCR), western blotting, immunohistochemistry, and a series of functional assays in vitro and in vivo to investigate the roles of HKDC1 in LUAD.Results: We discovered that HKDC1 was highly expressed in LUAD tissues and cell lines, and the positive expression of HKDC1 was correlated with aberrant clinicopathological characteristics in LUAD patients. Furthermore, HKDC1 could serve as a prognostic predictor for LUAD patients. Overexpression of HKDC1 promoted proliferation, migration, invasion, glycolysis, EMT and tumorigenicity, whereas knockdown of HKDC1 produced the opposite functional effects. Mechanistically, HKDC1 could regulate the AMPK/mTOR signaling pathway to perform its biological function.Conclusions: Our findings suggest that HKDC1 plays an oncogenic role in LUAD. Targeting this gene may provide a promising therapeutic target to delay LUAD progression.

scholarly journals MC1R Is a Prognostic Marker and Its Expression Is Correlated with MSI in Colorectal Cancer

2021 ◽  
Vol 43 (3) ◽  
pp. 1529-1547
Author(s):  
Lixiong Peng ◽  
Jiang Chang ◽  
Xilin Liu ◽  
Shiying Lu ◽  
Honglin Ren ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Poor Prognosis ◽  
Direct Sequencing ◽  
Clinicopathological Characteristics ◽  
Nucleotide Polymorphisms ◽  
Pigment Formation ◽  
P53 Expression ◽  
Normal Tissues ◽  
Genome Damage ◽  
Damage Repair

Melanocortin 1 receptor (MC1R) is thought to be a marker of poor prognosis and a potential target for the treatment of melanoma. Studies have found that MC1R promotes several tumor behaviors, including cell proliferation and differentiation, pigment formation, and genome damage repair. Some single-nucleotide polymorphisms (SNPs) of MC1R are involved in the occurrence and development of melanoma. A few studies have reported a relationship between MC1R and colorectal cancer (CRC). In this research, our objective was to examine MC1R expression and MC1R SNPs and investigate their correlation with the clinicopathological features of human CRC tissues. We evaluated MC1R mRNA expression by performing bioinformatic analyses on human CRC expression datasets. We used Western blotting and RT-qPCR to compare MC1R expression in CRC tissues with that in normal tissues, and MC1R SNPs in CRC tissues were detected by PCR-direct sequencing (DS). The expression of MC1R was significantly decreased in CRC tissues compared with normal tissue, and its expression was negatively associated with P53 expression, MLH1 expression, and PMS2 expression, and high MC1R expression was significantly associated with microsatellite instability (MSI). MC1R SNPs were also associated with the clinicopathological characteristics of CRC; for example, the rs2228479 locus genotype was correlated with Ki67 status, and the rs885479 locus genotype was correlated with age and T stage. In conclusion, MC1R plays a crucial role in the progression of CRC and may be a marker of poor prognosis in CRC.

Effects of Bcl-2, Bax and P53 Gene Protein Expressions in Gastric Cancer Tissue on the Apoptosis of Cancer Cells

2013 ◽  
Vol 423-426 ◽  
pp. 358-361
Author(s):  
Lei Zhang ◽  
Da Peng Li ◽  
Guan Nan Lu
Keyword(s):  
Gastric Cancer ◽  
P53 Protein ◽  
P53 Gene ◽  
Gastric Cancer Tissue ◽  
Normal Lung ◽  
Cancer Tissue ◽  
P53 Expression ◽  
Bax Protein ◽  
Significant Difference ◽  
Positive Rate

Objective: To investigate the expression of p53 gene in gastric cancer tissue and its correlation with bcl-2 and bax protein expression in relationship and discuss the significance of their correlation in clinic. Methods: Pathological specimens from 100 gastric cancer patients with complete medical data and 24 normal lung tissue specimens were selected. Immunohistochemical streptavidin-biotin-peroxidase assay was used to detect the expression of bcl-2, bax and p53 protein. Results: p53 expression was positively correlated with bcl-2 expression (Pearson's R =0.491, P <0.05). The positive expression of p53 was no significantly correlated with bax expression (P> 0.05). The positive rate of p53 expression in the well-differentiated gastric cancer tissues was 17.6%, the positive rate in the differentiated tissues was 90.9%, the positive rate in the poorly differentiated tissues was 72.7%, and There was a significant difference in the expression of p53 in the three tissues (P <0.05). The expression of p53 in the TNM staging showed that the positive rate in stage Iand IIwas 27.3%, the positive rate in stage III and stage IVwas 89.3%, the difference between them was significant (P <0.05). Conclusions: The expression of p53 gene has an obvious clinical significance for the assessment of degree of malignancy and the prognosis of gastric cancer. Bcl-2 and p53 gene expression could jointly promote the development of gastric cancer in a synergistic way by acting on different stages of apoptosis, or bcl-2s participating in p53-induced mitochondria-mediated apoptosis signaling pathways.

Positive Expression of MUC1 Gene Is a Poor Prognostic Factor in Acute Myelogenous Leukemia.

Blood ◽  
2006 ◽  
Vol 108 (11) ◽  
pp. 4294-4294
Author(s):  
Ren-wei Huang ◽  
Guo-wei Li ◽  
Dong-ning Wang ◽  
Xu-dong Li ◽  
Gui-zhen Lin ◽  
...  
Keyword(s):  
Prognostic Factor ◽  
Acute Leukemia ◽  
Residual Disease ◽  
Myelogenous Leukemia ◽  
Muc1 Expression ◽  
Poor Prognostic Factor ◽  
Positive Expression ◽  
Muc1 Gene ◽  
Pcr Products ◽  
Expression Rate

Abstract Objective: To study the expression of MUC1 in acute leukemia and its clinical significance. Methods: Expression of MUC1 mRNA was detected in 73 newly diagnosed and relapsed patients of acute leukemia by reverse transcriptase polymerase reaction(RT-PCR). The MUC1 positive PCR products were analyzed by digestion with pst I. With clinical observation, the relationship of expression of MUC1 gene and treatment results were done. Results: The expression of MUC1 was positive in 36 of 73 AL patients (49.3%). The MUC1 expression rate was 39.1% in ALL and 52.2% in AML and they show no significance difference. MUC1 gene was undetectable in 23 healthy subjects. Nineteen of 21 (90.5%) MUC1-negative non-M3 acute leukemia patients got CR while 14 of 22 (63.6%) MUC1-positive non-M3 acute leukemia patients got CR which showed significance difference (p<0.05); Only 9 of 16 cases of MUC1-positive non-M3 AML patients got CR(56.3%), while 10 of 11 patients of MUC1-negative non-M3 AML got CR(90.9%). The expression of MUC1 could turn negative after CR. There was no mutation of MUC1 gene correlating with digested site of pst I. Conclusion: MUC1 expression is observed in some acute leukemia patients. The positive expression of MUC1 is not different between AML and ALL. The AML patients whose MUC1 gene showed positive got lower CR rate. It indicates that the expression of MUC1 can be used as a poor prognostic factor in AML and a marker for detection of minimal residual disease in AL.

scholarly journals The Clinical Significance of PR, ER, NF-κB, and TNF-αin Breast Cancer

2014 ◽  
Vol 2014 ◽  
pp. 1-7 ◽  
Author(s):  
Xian-Long Zhou ◽  
Wei Fan ◽  
Gui Yang ◽  
Ming-Xia Yu
Keyword(s):  
Breast Cancer ◽  
Progesterone Receptors ◽  
Tumor Grade ◽  
Age At Menarche ◽  
Human Breast ◽  
Positive Expression ◽  
History Of ◽  
Expression Rate ◽  
Status Number ◽  
Necrosis Factor

Objectives. To investigate the expression of estrogen (ER), progesterone receptors (PR), nuclear factor-κB (NF-κB), and tumor necrosis factor-α(TNF-α) in human breast cancer (BC), and the correlation of these four parameters with clinicopathological features of BC.Methods and Results. We performed an immunohistochemical SABC method for the identification of ER, PR, NF-κB, and TNF-αexpression in 112 patients with primary BC. The total positive expression rate of ER, PR, NF-κB, and TNF-αwas 67%, 76%, 84%, and 94%, respectively. The expressions of ER and PR were correlated with tumor grade, TNM stage, and lymph node metastasis (P<0.01, resp.), but not with age, tumor size, histological subtype, age at menarche, menopause status, number of pregnancies, number of deliveries, and family history of cancer. Expressions of ER and PR were both correlated with NF-κB and TNF-αexpression (P<0.05, resp.). Moreover, there was significant correlation between ER and PR(P<0.0001)as well as between NF-κB and TNF-αexpression(P<0.05).Conclusion. PR and ER are highly expressed, with significant correlation with NF-κB and TNF-αexpression in breast cancer. The important roles of ER and PR in invasion and metastasis of breast cancer are probably associated with NF-κB and TNF-αexpression.

Correlations of Bcl-2 and Survivin Gene Protein Expressions in Colorectal Cancer

2013 ◽  
Vol 423-426 ◽  
pp. 362-365 ◽  
Author(s):  
Yue Ma ◽  
Hong Sheng Wang
Keyword(s):  
Colorectal Cancer ◽  
Normal Tissues ◽  
Positive Expression ◽  
Significant Difference ◽  
Protein Expressions ◽  
Positive Rate ◽  
Poorly Differentiated ◽  
Well Differentiated ◽  
Colorectal Cancer Patients ◽  
Cancer Tissues

Objective: In this study, immunohistochemical streptavidinbiotin-peroxidase (S-P method) was used to detect the correlation of gene proteins related to apoptosis, such as Bcl-2 and Survivin in colorectal carcinoma. Methods: Pathological specimens from 46 colorectal cancer patients and 8 normal tissues around the tumor specimens were selected. Immunohistochemical streptavidin-biotin-peroxidase assay was used to detect the expression of Bcl-2 and Surviving protein. Results: In 25 cases of Bcl-2 positive expression, there were 24 cases of Survivin positive expression, accounting for 96%; while there were 8 cases of Survivin positive expression in 21 cases of Bcl-2 negative expression, accounting for 38.1%, showing the expression of Bcl-2 and the expression of Survivin was positively correlated (Pearsons R= 0.627, P<0.01). In 15 cases of well-differentiated colorectal cancer tissues, there were 6 Cases of Survivin positive expression, and the positive rate was 40%; in 17 cases of moderately differentiated colorectal cancer tissues, there were 17 cases, and the positive rate was 100%; in 14 cases of poorly differentiated colorectal cancer tissues, there were 9 cases, and the positive rate was 64.29%. The statistical analysis showed that the Survivin positive expression in the three colorectal cancer tissues presented a significant difference (P <0.01). Results: The positive expression of Survivin protein was directly correlated to that of Bcl-2, which suggested that both of them acted on different stages of apoptosis to promote jointly the development of colorectal cancer in a synergistic way.

scholarly journals Expression of HE4 in Endometrial Cancer and Its Clinical Significance

2015 ◽  
Vol 2015 ◽  
pp. 1-8 ◽  
Author(s):  
Xiao Li ◽  
Yiping Gao ◽  
Mingzi Tan ◽  
Huiyu Zhuang ◽  
Jian Gao ◽  
...  
Keyword(s):  
Endometrial Cancer ◽  
Cancer Patients ◽  
Clinical Stage ◽  
Atypical Hyperplasia ◽  
Clinicopathological Parameters ◽  
Normal Endometrium ◽  
Positive Expression ◽  
Significant Difference ◽  
Expression Rate ◽  
Degree Of Differentiation

The main aims of this study were to determine the expression of human epididymis protein 4 (HE4) in endometrial cancer and to explore the relationships between HE4 expression, clinicopathological parameters, and prognosis. Immunohistochemistry was used to detect HE4 expression in 102 cases of endometrial cancer, 30 cases of endometrial atypical hyperplasia, and 20 cases of normal endometrium. The positive expression rate of HE4 in endometrial carcinoma was 84.62%, significantly higher than 66.67% in atypical hyperplasia (P<0.05) and 15.00% in normal endometrium (P<0.0.01). With the exception of stage II, HE4 expression in endometrial cancer showed an increasing tendency with increased clinical stage (P<0.05). The positive expression rate of HE4 increased with a decrease in the degree of differentiation. A statistically significant difference was observed between the highly differentiated group and the poorly differentiated group (P<0.05). Mortality in endometrial cancer patients with high HE4 expression was significantly higher than that in patients with low HE4 expression (P<0.05). Endometrial cancer patients with high HE4 expression have a poor prognosis.

Sign in / Sign up

Export Citation Format

Share Document